Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Peptide Bonds

Peptide Bonds

A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Regional abnormalities of cardiac sympathetic innervation in athletes with nonischaemic left ventricular scar and exercise-related ventricular arrhythmias.

European heart journal open·2026

Same author

Interpreting the athlete's ECG to prevent sudden death: An old tool in constant evolution.

International journal of cardiology·2026

Same author

Sudden Death in Young Competitive Athletes Due to Arrhythmogenic Cardiomyopathy: A 4-Decade National Referral Center Experience.

Circulation. Arrhythmia and electrophysiology·2026

Same author

Progressively complex exercise-induced ventricular arrhythmias unveiling catecholaminergic polymorphic ventricular tachycardia associated with a novel RYR2 variant in a competitive athlete: a case report.

European heart journal. Case reports·2026

Same author

Generation of membrane-permeable cyclic peptides inhibiting protein-protein interaction.

Nature chemical biology·2026

Same author

ChatGPT's Limitations in Athlete ECG Interpretation: Evidence from a Multicenter Diagnostic Study.

Journal of cardiovascular development and disease·2026

Search research articles

Related Experiment Video

Updated: Mar 7, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

Cyclic peptide therapeutics: past, present and future.

Alessandro Zorzi¹, Kaycie Deyle¹, Christian Heinis¹

¹Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.

Current Opinion in Chemical Biology

|March 2, 2017

Summary

Cyclic peptides offer therapeutic advantages like high binding affinity and low toxicity. Novel de novo design methods are expanding their use beyond natural products for future drug development.

More Related Videos

Constructing Cyclic Peptides Using an On-Tether Sulfonium Center

Constructing Cyclic Peptides Using an On-Tether Sulfonium Center

Published on: September 28, 2022

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Published on: September 19, 2022

Related Experiment Videos

Last Updated: Mar 7, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

Constructing Cyclic Peptides Using an On-Tether Sulfonium Center

Constructing Cyclic Peptides Using an On-Tether Sulfonium Center

Published on: September 28, 2022

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Published on: September 19, 2022

Area of Science:

Pharmaceutical Science
Medicinal Chemistry
Drug Discovery

Background:

Cyclic peptides possess desirable therapeutic properties including high binding affinity, target selectivity, and low toxicity.
Over 40 cyclic peptide drugs are in clinical use, with approximately one new drug approved annually.
The majority of approved cyclic peptides originate from natural products like antimicrobials and peptide hormones.

Purpose of the Study:

To highlight the growing importance of cyclic peptides in therapeutic development.
To discuss the impact of novel design techniques on expanding the scope of cyclic peptide applications.
To project the future clinical use of de novo designed cyclic peptides.

Main Methods:

Review of existing literature on cyclic peptide therapeutics.
Analysis of trends in cyclic peptide drug approval and clinical evaluation.
Examination of rational design and in vitro evolution techniques for de novo cyclic peptide development.

Main Results:

Cyclic peptides are a well-established therapeutic modality with a consistent market entry rate.
Natural products remain the primary source for approved cyclic peptides.
Emerging de novo design techniques are yielding novel cyclic peptide ligands for challenging targets.

Conclusions:

De novo designed cyclic peptides represent a significant advancement, offering solutions for targets lacking natural ligands.
The increasing number of de novo developed cyclic peptides in clinical evaluation suggests their future therapeutic importance.
Cyclic peptides, both natural and de novo designed, are poised for continued growth in the pharmaceutical landscape.